Market Overview
The India dry age-related macular degeneration (AMD) market is experiencing significant growth, driven by rising prevalence of AMD among the aging population. Dry AMD is a leading cause of vision loss in older adults, characterized by gradual deterioration of the macula. The market is projected to grow through 2030, fueled by demographic trends, increasing awareness, and expanding treatment options. India's elderly population is growing rapidly, with approximately 10% of adults over 60 affected by AMD.

The India Dry Age-Related Macular Degeneration AMD Market benefits from improving healthcare infrastructure, expanding access to ophthalmology specialists, and growing awareness of eye health. Government initiatives promoting eye care and screening programs are supporting early diagnosis.

Current Market Landscape
Key players include Novartis, Roche, and Bayer, alongside Indian pharmaceutical companies. Treatment options for dry AMD are limited compared to wet AMD, though emerging therapies offer hope. Ophthalmology clinics and hospital eye departments are primary providers.

Emerging Trends
Complement inhibitors targeting the complement pathway are emerging as potential treatments. Gene therapy approaches are in clinical trials. Nutritional supplements including AREDS2 formulations are widely used for prevention.

Future Outlook
The India dry AMD market is expected to grow significantly, driven by rising prevalence and new treatment approvals.

Conclusion
Rising prevalence of dry AMD is driving growth in India's market, creating demand for innovative treatments.

FAQ
Q1: What is dry AMD?
A: A progressive eye condition causing vision loss in older adults.
Q2: What drives market growth?
A: Aging population and increasing awareness drive demand.

#DryAMD #EyeHealth #IndiaHealthcare